镰孢病的新治疗选择:专利审查(2008-2023)。

IF 4.2 2区 生物学 Q2 MICROBIOLOGY
Izadora Dillis Faccin, Túlio Máximo Salomé, Gleyce Hellen de Almeida de Souza, Leonardo da Costa Xavier, Izabel Almeida Alves, Vanessa Castro Felix Lima, Fabíola Lucini, Simone Simionatto, Luana Rossato
{"title":"镰孢病的新治疗选择:专利审查(2008-2023)。","authors":"Izadora Dillis Faccin, Túlio Máximo Salomé, Gleyce Hellen de Almeida de Souza, Leonardo da Costa Xavier, Izabel Almeida Alves, Vanessa Castro Felix Lima, Fabíola Lucini, Simone Simionatto, Luana Rossato","doi":"10.3390/jof11060463","DOIUrl":null,"url":null,"abstract":"<p><p>Fusariosis is an infection caused by the fungus <i>Fusarium</i> spp., which is pathogenic to both plants and humans. The disease presents several clinical manifestations and epidemiological patterns. Current treatment relies on azoles and polyenes, but increasing antifungal resistance requires the exploration of new therapeutic options. This study reviewed patents related to the treatment of Fusariosis from the last 15 years (up to June 2023). The search identified 318 patents, categorized by identification code, publication date, type of application and mechanism of action, using the International Patent Classification and Cooperative Patent Classification systems. In addition, we conducted a bibliographic search in the PubMed database using the same criteria to identify the number of scientific articles. Of the 318 patents, 21 targeted Fusarium infections in humans. The years 2014 and 2018 stood out with three patents each, while the same period recorded an average of 58 published articles. The patents addressed mechanisms such as drug delivery, gene expression, immunotherapy, engineered drugs, and novel compounds. This research highlights the urgent need for continued innovation in therapeutic technologies to effectively treat <i>Fusarium</i> wilt.</p>","PeriodicalId":15878,"journal":{"name":"Journal of Fungi","volume":"11 6","pages":""},"PeriodicalIF":4.2000,"publicationDate":"2025-06-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12194352/pdf/","citationCount":"0","resultStr":"{\"title\":\"New Therapeutic Options for Fusariosis: A Patent Review (2008-2023).\",\"authors\":\"Izadora Dillis Faccin, Túlio Máximo Salomé, Gleyce Hellen de Almeida de Souza, Leonardo da Costa Xavier, Izabel Almeida Alves, Vanessa Castro Felix Lima, Fabíola Lucini, Simone Simionatto, Luana Rossato\",\"doi\":\"10.3390/jof11060463\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Fusariosis is an infection caused by the fungus <i>Fusarium</i> spp., which is pathogenic to both plants and humans. The disease presents several clinical manifestations and epidemiological patterns. Current treatment relies on azoles and polyenes, but increasing antifungal resistance requires the exploration of new therapeutic options. This study reviewed patents related to the treatment of Fusariosis from the last 15 years (up to June 2023). The search identified 318 patents, categorized by identification code, publication date, type of application and mechanism of action, using the International Patent Classification and Cooperative Patent Classification systems. In addition, we conducted a bibliographic search in the PubMed database using the same criteria to identify the number of scientific articles. Of the 318 patents, 21 targeted Fusarium infections in humans. The years 2014 and 2018 stood out with three patents each, while the same period recorded an average of 58 published articles. The patents addressed mechanisms such as drug delivery, gene expression, immunotherapy, engineered drugs, and novel compounds. This research highlights the urgent need for continued innovation in therapeutic technologies to effectively treat <i>Fusarium</i> wilt.</p>\",\"PeriodicalId\":15878,\"journal\":{\"name\":\"Journal of Fungi\",\"volume\":\"11 6\",\"pages\":\"\"},\"PeriodicalIF\":4.2000,\"publicationDate\":\"2025-06-18\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12194352/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Fungi\",\"FirstCategoryId\":\"99\",\"ListUrlMain\":\"https://doi.org/10.3390/jof11060463\",\"RegionNum\":2,\"RegionCategory\":\"生物学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"MICROBIOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Fungi","FirstCategoryId":"99","ListUrlMain":"https://doi.org/10.3390/jof11060463","RegionNum":2,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MICROBIOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

镰刀菌病是由真菌镰刀菌引起的一种感染,对植物和人类都具有致病性。该病有多种临床表现和流行病学特征。目前的治疗依赖于唑类和多烯类,但抗真菌耐药性的增加需要探索新的治疗选择。本研究回顾了过去15年(截至2023年6月)与镰孢菌病治疗相关的专利。检索确定了318项专利,使用国际专利分类和合作专利分类系统,按识别码、公布日期、申请类型和作用机制进行了分类。此外,我们在PubMed数据库中进行了书目检索,使用相同的标准来确定科学文章的数量。在318项专利中,有21项针对人类镰刀菌感染。2014年和2018年各有3项专利,而同期平均发表了58篇文章。这些专利涉及药物传递、基因表达、免疫治疗、工程药物和新化合物等机制。本研究强调了持续创新治疗技术以有效治疗枯萎病的迫切需要。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
New Therapeutic Options for Fusariosis: A Patent Review (2008-2023).

Fusariosis is an infection caused by the fungus Fusarium spp., which is pathogenic to both plants and humans. The disease presents several clinical manifestations and epidemiological patterns. Current treatment relies on azoles and polyenes, but increasing antifungal resistance requires the exploration of new therapeutic options. This study reviewed patents related to the treatment of Fusariosis from the last 15 years (up to June 2023). The search identified 318 patents, categorized by identification code, publication date, type of application and mechanism of action, using the International Patent Classification and Cooperative Patent Classification systems. In addition, we conducted a bibliographic search in the PubMed database using the same criteria to identify the number of scientific articles. Of the 318 patents, 21 targeted Fusarium infections in humans. The years 2014 and 2018 stood out with three patents each, while the same period recorded an average of 58 published articles. The patents addressed mechanisms such as drug delivery, gene expression, immunotherapy, engineered drugs, and novel compounds. This research highlights the urgent need for continued innovation in therapeutic technologies to effectively treat Fusarium wilt.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Journal of Fungi
Journal of Fungi Medicine-Microbiology (medical)
CiteScore
6.70
自引率
14.90%
发文量
1151
审稿时长
11 weeks
期刊介绍: Journal of Fungi (ISSN 2309-608X) is an international, peer-reviewed scientific open access journal that provides an advanced forum for studies related to pathogenic fungi, fungal biology, and all other aspects of fungal research. The journal publishes reviews, regular research papers, and communications in quarterly issues. Our aim is to encourage scientists to publish their experimental and theoretical results in as much detail as possible. Therefore, there is no restriction on paper length. Full experimental details must be provided so that the results can be reproduced.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信